Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management
TORONTO, ON, Sep 17, 2024 – (ACN Newswire via SeaPRwire.com) – Ripple Therapeutics today announced a collaboration and option-to-license agreement with AbbVie to develop RTC-620, […]